The estimated Net Worth of Mark S. Levine is at least $6.15 millió dollars as of 21 August 2024. Mr. Levine owns over 3,295 units of Flexion Therapeutics Inc stock worth over $3,033,610 and over the last 10 years he sold FLXN stock worth over $1,903,448. In addition, he makes $1,212,490 as General Counsel and Corporate Secretary at Flexion Therapeutics Inc.
Mark has made over 20 trades of the Flexion Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 3,295 units of FLXN stock worth $104,979 on 21 August 2024.
The largest trade he's ever made was exercising 17,500 units of Flexion Therapeutics Inc stock on 1 June 2017 worth over $90,825. On average, Mark trades about 3,041 units every 71 days since 2014. As of 21 August 2024 he still owns at least 330,099 units of Flexion Therapeutics Inc stock.
You can see the complete history of Mr. Levine stock trades at the bottom of the page.
Mark Levine J.D. serves as General Counsel and Corporate Secretary of the Company. Mark Levine joined us as General Counsel and Corporate Secretary in June 2017. Prior to joining us, from 2014 to 2017, Mr. Levine served as Senior Vice President, General Counsel and Corporate Secretary at Minerva Neurosciences, Inc. where he managed all legal affairs for a biopharmaceutical company focused on the development of a portfolio of candidates to treat central nervous system diseases. Prior to Minerva, Mr. Levine held senior legal positions at athenahealth, Inc. and Clinical Data, Inc., a biopharmaceutical company that was acquired by Forest Laboratories, Inc. in 2011. Mr. Levine earned his B.A. in political science from Binghamton University, SUNY, and his J.D. from Washington University School of Law in St. Louis.
As the General Counsel and Corporate Secretary of Flexion Therapeutics Inc, the total compensation of Mark Levine at Flexion Therapeutics Inc is $1,212,490. There are 3 executives at Flexion Therapeutics Inc getting paid more, with Michael Clayman having the highest compensation of $3,777,360.
Mark Levine is 47, he's been the General Counsel and Corporate Secretary of Flexion Therapeutics Inc since 2017. There are 15 older and no younger executives at Flexion Therapeutics Inc. The oldest executive at Flexion Therapeutics Inc is Samuel Colella, 80, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR, NEW YORK, NY, 10018.
Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon és Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.
Flexion Therapeutics Inc executives and other stock owners filed with the SEC include: